Loading
A phase 2 trial of carboplatin, pemetrexed and zipalertinib in lung cancer, run by Jonsson Comprehensive Cancer Center, not yet recruiting.
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07229339 by Jonsson Comprehensive Cancer Center, with a registry enrolment figure of 16 participants, started 2027-06-01 and due to reach its primary completion in 2029-06-01. Interventions recorded: Biospecimen Collection; Carboplatin; Computed Tomography; Magnetic Resonance Imaging; Pemetrexed; Positron Emission Tomography; Zipalertinib. Conditions listed: Lung Non-Squamous Non-Small Cell Carcinoma. Primary outcome: Major pathologic response. Lung eligibility wording from the registry: "* Histologically confirmed non-squamous NSCLC performed within 90 days of enrollment with EGFR Ex20Ins-mutated (addition of 1 or more amino acids) or uncommon/compound EGFR mutations (E709X, G719X, L747X, S758I, and/or L861Q) in tumor tissue or blood; any one of these mutations would qualify if comp". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Zipalertinib, Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.